Bristol-Myers Squibb (TICKER: BMY) Benchmark And Performance Data

there are 10 of samples in the benchmark for Bristol-Myers Squibb in year 2022 in 2022. The total inventory for Bristol-Myers Squibb was $4,293,000,000.00 in 2019. The total inventory for Bristol-Myers Squibb was $2,095,000,000.00 in 2021. The total inventory for Bristol-Myers Squibb was $2,074,000,000.00 in 2020. The total inventory for Bristol-Myers Squibb was $1,657,000,000.00 in 2012. The total inventory for Bristol-Myers Squibb was $1,560,000,000.00 in 2014. The total inventory for Bristol-Myers Squibb was $1,498,000,000.00 in 2013. The total inventory for Bristol-Myers Squibb was $1,241,000,000.00 in 2016. The total inventory for Bristol-Myers Squibb was $1,221,000,000.00 in 2015. The total inventory for Bristol-Myers Squibb was $1,195,000,000.00 in 2018. The total inventory for Bristol-Myers Squibb was $1,166,000,000.00 in 2017. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $7,690,000,000.00 in 2021. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $7,661,000,000.00 in 2020. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $5,699,000,000.00 in 2014. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $5,175,000,000.00 in 2012. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $5,104,000,000.00 in 2013. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $5,001,000,000.00 in 2015. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $4,979,000,000.00 in 2016. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $4,871,000,000.00 in 2019. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $4,751,000,000.00 in 2017. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $4,551,000,000.00 in 2018. The sales, general, and administrative (SGA) for Bristol-Myers Squibb was $$7,814,000,000 in 2022. The revenue volatility for Bristol-Myers Squibb was 27.97% in 2022. The market capitalization for Bristol-Myers Squibb was $164,395,000,000.00 in 2016. The market capitalization for Bristol-Myers Squibb was $155,485,563,711.00 in 2015. The market capitalization for Bristol-Myers Squibb was $152,977,236,966.00 in 2018. The market capitalization for Bristol-Myers Squibb was $151,795,289,182.00 in 2017. The market capitalization for Bristol-Myers Squibb was $148,481,627,611.00 in 2012. The market capitalization for Bristol-Myers Squibb was $145,551,000,000.00 in 2019. The market capitalization for Bristol-Myers Squibb was $134,239,550,000.00 in 2014. The market capitalization for Bristol-Myers Squibb was $133,591,550,000.00 in 2020. The market capitalization for Bristol-Myers Squibb was $131,336,390,803.00 in 2013. The market capitalization for Bristol-Myers Squibb was $121,251,533,534.00 in 2021. The market capitalization for Bristol-Myers Squibb was $$99,113,000,000 in 2022. The gross revenue for Bristol-Myers Squibb was $46,385,000,000.00 in 2021. The gross revenue for Bristol-Myers Squibb was $42,518,000,000.00 in 2020. The gross revenue for Bristol-Myers Squibb was $26,145,000,000.00 in 2019. The gross revenue for Bristol-Myers Squibb was $22,561,000,000.00 in 2018. The gross revenue for Bristol-Myers Squibb was $20,776,000,000.00 in 2017. The gross revenue for Bristol-Myers Squibb was $19,427,000,000.00 in 2016. The gross revenue for Bristol-Myers Squibb was $17,621,000,000.00 in 2012. The gross revenue for Bristol-Myers Squibb was $16,560,000,000.00 in 2015. The gross revenue for Bristol-Myers Squibb was $16,385,000,000.00 in 2013. The gross revenue for Bristol-Myers Squibb was $15,879,000,000.00 in 2014. The gross revenue for Bristol-Myers Squibb was $$46,159,000,000 in 2022. The gross margin for Bristol-Myers Squibb was $19.72% in 2022. The days sales outstanding for Bristol-Myers Squibb was 64 days in 2022. The days payable outstanding for Bristol-Myers Squibb was 108 days in 2022. The days of inventory for Bristol-Myers Squibb was $80 in 2022. The cost of goods sold (COGS) for Bristol-Myers Squibb was 21.96% in 2022. The cost of goods sold (COGS) for Bristol-Myers Squibb was $9,940,000,000.00 in 2021. The cost of goods sold (COGS) for Bristol-Myers Squibb was $8,078,000,000.00 in 2019. The cost of goods sold (COGS) for Bristol-Myers Squibb was $6,467,000,000.00 in 2018. The cost of goods sold (COGS) for Bristol-Myers Squibb was $6,014,000,000.00 in 2017. The cost of goods sold (COGS) for Bristol-Myers Squibb was $4,969,000,000.00 in 2016. The cost of goods sold (COGS) for Bristol-Myers Squibb was $4,619,000,000.00 in 2013. The cost of goods sold (COGS) for Bristol-Myers Squibb was $4,610,000,000.00 in 2012. The cost of goods sold (COGS) for Bristol-Myers Squibb was $3,932,000,000.00 in 2014. The cost of goods sold (COGS) for Bristol-Myers Squibb was $3,909,000,000.00 in 2015. The cost of goods sold (COGS) for Bristol-Myers Squibb was $11,773,000,000.00 in 2020. The cost of goods sold (COGS) for Bristol-Myers Squibb was $$10,137,000,000 in 2022. The cash to cash cycle time for Bristol-Myers Squibb was 36 in 2022. The annual percentage growth rate of Bristol-Myers Squibb was 0.00% in 2022. Bristol-Myers Squibb in its benchmark peer group, had rank 5 for gross revenue in 2022. Bristol-Myers Squibb in its benchmark peer group, had rank 5 days for days sales outstanding in 2022. Bristol-Myers Squibb in its benchmark peer group, had rank 3 for sales growth in 2022. Bristol-Myers Squibb in its benchmark peer group, had rank 2 for cost of goods sold as a percent of revenue in 2022. Bristol-Myers Squibb in its benchmark peer group, had rank 2 days for days of inventory in 2022. Bristol-Myers Squibb in its benchmark peer group, had rank 1 for cash to cash cycle time in 2022. Bristol-Myers Squibb headquarters region is East. Bristol-Myers Squibb has ticker symbol BMY. Bristol-Myers Squibb has the following profile: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.. Bristol-Myers Squibb has primary indstury Drug Manufacturers - General. Bristol-Myers Squibb had a $$12,264,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Bristol-Myers Squibb had Organon, and Eli Lilly, and AbbVie, and Pfizer, and Bristol-Myers Squibb, and Amgen, and Gilead Sciences, and Biogen, and Johnson & Johnson, and Merck benchmark peer companies for its SIC code in 2022. Bristol-Myers Squibb had 59.12% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Bristol-Myers Squibb had 34,300 number of employees in 2022. Bristol-Myers Squibb had 337 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Bristol-Myers Squibb had 3 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Bristol-Myers Squibb had 13.63% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Bristol-Myers Squibb had 10.86% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Bristol-Myers Squibb had 0.02% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Bristol-Myers Squibb had 0 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Bristol-Myers Squibb can reduce overall cost by $$47,841,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Bristol-Myers Squibb can reduce inventory with practices including SKU Reduction in 2022. Bristol-Myers Squibb can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Bristol-Myers Squibb can reduce inventory with practices including Forecast Accuracy in 2022. Bristol-Myers Squibb can reduce inventory with practices including Demand Shaping in 2022. Bristol-Myers Squibb can reduce days sales outstanding with practices including in 2022. Bristol-Myers Squibb can increase sales revenue by $$12,264,000,000 improving sales performance to next benchmark tier in 2022. Bristol-Myers Squibb can increase revenue growth by $$10,000,000 by improving growth performance to next benchmark tier in 2022. Bristol-Myers Squibb can increase overall revenue by $$12,273,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Bristol-Myers Squibb can increase days payables outstanding with practices including Strategic Sourcing in 2022. Bristol-Myers Squibb can increase days payables outstanding by $4,123,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Bristol-Myers Squibb can improve total financial performance by $$107,184,000,000 by improving revenue, costs, and working capital in 2022. Bristol-Myers Squibb can decrease overall working capital by $$47,070,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Bristol-Myers Squibb can decrease inventory days by $42,618,000,000 days by reducing inventory days to next benchmark tier in 2022. Bristol-Myers Squibb can decrease days sales outstanding by $329,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. Bristol-Myers Squibb can accelerate revenue growth practices including Revenue-optimized Planning in 2022. Bristol-Myers Squibb can accelerate revenue growth practices including Pricing Optimization in 2022. Bristol-Myers Squibb can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 82 days was the measured parity or middle performance level for cash to cash cycle time in Bristol-Myers Squibb's peer group in 2022. 79 days was the measured superior or top ten performance level for days of inventory in Bristol-Myers Squibb's peer group in 2022. 68 days was the measured advantage or top third performance level for cash to cash cycle time in Bristol-Myers Squibb's peer group in 2022. 66 days was the measured parity or middle performance level for days sales outstanding in Bristol-Myers Squibb's peer group in 2022. 61 days was the measured advantage or top third performance level for days sales outstanding in Bristol-Myers Squibb's peer group in 2022. 6.73% was the measured superior or top ten performance level for sales volatility in Bristol-Myers Squibb's peer group in 2022. 56 days was the measured superior or top ten performance level for days sales outstanding in Bristol-Myers Squibb's peer group in 2022. 37.46% was the measured superior or top ten performance level for gross margin in Bristol-Myers Squibb's peer group in 2022. 37 days was the measured superior or top ten performance level for cash to cash cycle time in Bristol-Myers Squibb's peer group in 2022. 26.85% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Bristol-Myers Squibb's peer group in 2022. 22.98% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Bristol-Myers Squibb's peer group in 2022. 21.84% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Bristol-Myers Squibb's peer group in 2022. 14.35% was the measured parity or middle performance level for sales volatility in Bristol-Myers Squibb's peer group in 2022. 129 days was the measured parity or middle performance level for days of inventory in Bristol-Myers Squibb's peer group in 2022. 100 days was the measured advantage or top third performance level for days of inventory in Bristol-Myers Squibb's peer group in 2022. 10.93% was the measured advantage or top third performance level for sales volatility in Bristol-Myers Squibb's peer group in 2022. 0.03% was the measured superior or top ten performance level for sales growth in Bristol-Myers Squibb's peer group in 2022. 0.00% was the measured advantage or top third performance level for sales growth in Bristol-Myers Squibb's peer group in 2022. -0.01% was the measured parity or middle performance level for sales growth in Bristol-Myers Squibb's peer group in 2022. $33.59% was the measured advantage or top third performance level for gross margin in Bristol-Myers Squibb's peer group in 2022. $30.58% was the measured parity or middle performance level for gross margin in Bristol-Myers Squibb's peer group in 2022. $$95,482,000,000 was the measured superior or top ten performance level for gross revenue in Bristol-Myers Squibb's peer group in 2022. $$58,423,000,000 was the measured advantage or top third performance level for gross revenue in Bristol-Myers Squibb's peer group. $$37,350,000,000 was the measured parity or middle performance level for gross revenue in Bristol-Myers Squibb's peer group in 2022.